Utilization of Bone-Anchored Annular Defect Closure to Prevent Reherniation Following Lumbar Discectomy: Overcoming Barriers to Clinical Adoption and Market Access.
PMID: 38569929 ·
M, o, r, g, a, n, , P, , L, o, r, i, o, ;, , W, i, l, l, i, a, m, , C, , W, a, t, t, e, r, s, ;, , B, e, t, s, y, , H, , G, r, u, n, c, h, ;, , A, n, d, r, e, w, , K, , M, e, t, z, g, e, r, ;, , K, a, i, -, U, w, e, , L, e, w, a, n, d, r, o, w, s, k, i, ;, , J, o, n, , E, , B, l, o, c, k, ;, , G, u, n, n, a, r, , B, , J, , A, n, d, e, r, s, s, o, n
Anzeige
Zusammenfassung
While achieving premarket approval from the US Food and Drug Administration represents a significant milestone in the development and commercialization of a Class III medical device, the aftermath endeavor of gaining market access can be daunting. This article provides a case study of the Barricaid annular closure device (Barricaid), a reherniation reduction device, which has been demonstrated to decrease the risk of suffering a recurrent lumbar intervertebral disc herniation. Following Food and
Anzeige
Offizielle Quelle
Auf PubMed ansehen →Daten aus PubMed / NCBI. Den Volltext und die aktuellsten Informationen finden Sie stets im offiziellen Eintrag.